scispace - formally typeset
Open AccessJournal ArticleDOI

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Reads0
Chats0
TLDR
This AASLD 2018 Hepatitis B Guidance provides a data-supported approach to screening, prevention, diagnosis, and clinical management of patients with hepatitis B.
About
This article is published in Hepatology.The article was published on 2018-04-01 and is currently open access. It has received 2399 citations till now. The article focuses on the topics: Hepatitis B & Mass screening.

read more

Citations
More filters
Journal ArticleDOI

Restoration of type I interferon signaling in intrahepatically primed CD8+ T cells promotes functional differentiation

TL;DR: In this paper, the expression profile of intrahepatically primed, dysfunctional HBV-specific CD8+ T cells with that of systemically primed, functional effector counterparts was compared.
Journal ArticleDOI

Partial Virological Response after 2 Years of Entecavir Therapy Increases the Risk of Hepatocellular Carcinoma in Patients with Hepatitis B Virus-Associated Cirrhosis

TL;DR: Older age, PVR, and higher FIB-4 index after 2 years of ETV therapy were independent risk factors for HCC, and efforts to accomplish a complete virological response and reduce the FIB -4 index should be made.
Journal ArticleDOI

Cytokines predict virological response in chronic hepatitis B patients receiving peginterferon alfa-2a therapy.

TL;DR: It is found that cytokine levels before and during treatment may represent potential biomarkers to select CHB patients who can respond to PEG-IFN, and cytokines can be used as an indicator of antiviral drug selection before CHB treatment.
Journal ArticleDOI

Efficacy of long-term tenofovir disoproxil fumarate therapy in chronic hepatitis B patients with partial virologic response in real practice.

TL;DR: The vast majority of patients achieved virologic response (VR) during continuous TDF therapy, thus TDF treatment can be maintained in nucleos(t)ide-naïve patients with PVR at week 48, especially in those with low viremia.
References
More filters
Journal ArticleDOI

Management of hepatocellular carcinoma.

TL;DR: The prevention of Cirrhosis can prevent the development of HCC and progression from chronic HCV infection to advanced fibrosis or cirrhosis may be prevented in 40% of patients who are sustained responders to new antiviral strategies, such as pegylated interferon and ribavirin.
Journal ArticleDOI

AASLD guidelines for the treatment of hepatocellular carcinoma

TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Journal ArticleDOI

Chronic hepatitis B: Update 2009

TL;DR: The 2009 update of the American Association for the Study of Liver Diseases (AASLD) Practice Guidelines for Management of Chronic Hepatitis B is now posted online at www.aasld.org, and the recommendation for first-line oral antiviral medications has been changed to tenofovir or entecavir, and adefovir has been moved to second-line Oral antiviral medication.
Journal ArticleDOI

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

TL;DR: More efficacious treatments, mass immunization programs, and safe injection techniques are essential for eliminating HBV infection and reducing global HBV‐related morbidity and mortality.
Related Papers (5)

Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study

Devin Razavi-Shearer, +195 more